Cell-mimicking nanodecoys neutralize SARS-CoV-2 and mitigate lung injury in a non-human primate model of COVID-19
Source abstract
Abstract
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has grown into a global pandemic, and only a few antiviral treatments have been approved to date. Angiotensin-converting enzyme 2 (ACE2) plays a fundamental role in SARS-CoV-2 pathogenesis because it allows viral entry into host cells. Here we show that ACE2 nanodecoys derived from human lung spheroid cells (LSCs) can bind and neutralize SARS-CoV-2 and protect the host lung cells from infection. In mice, these LSC-nanodecoys were delivered via inhalation therapy and resided in the lungs for over 72 h post-delivery. Furthermore, inhalation of the LSC-nanodecoys accelerated clearance of SARS-CoV-2 mimics from the lungs, with no observed toxicity. In cynomolgus macaques challenged with live SARS-CoV-2, four doses of these nanodecoys delivered by inhalation promoted viral clearance and reduced lung injury. Our results suggest that LSC-nanodecoys can serve as a potential therapeutic agent for treating COVID-19.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: SARS-CoV-2 and COVID-19 Research · COVID-19 Impact on Reproduction · COVID-19 Clinical Research Studies
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (32)
Show source-provided references
1. Wang, C., Horby, P. W., Hayden, F. G. & Gao, G. F. A novel coronavirus outbreak of global health concern. Lancet 395, 470–473 (2020).10.1016/S0140-6736(20)30185-9 ↗
2. Wang, D. et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 323, 1061–1069 (2020).10.1001/jama.2020.1585 ↗
3. Zhao, S. et al. Preliminary estimation of the basic reproduction number of novel coronavirus (2019-nCoV) in China, from 2019 to 2020: a data-driven analysis in the early phase of the outbreak. Int. J. Infect. Dis. 92, 214–217 (2020).10.1016/j.ijid.2020.01.050 ↗
4. Yuan, J., Li, M., Lv, G. & Lu, Z. K. Monitoring transmissibility and mortality of COVID-19 in Europe. Int. J. Infect. Dis. 95, 311–315 (2020).10.1016/j.ijid.2020.03.050 ↗
5. Ziegler, C. G. K. et al. SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues. Cell 181, 1016–1035.e19 (2020).10.1016/j.cell.2020.04.035 ↗
6. Henry, E. et al. Adult lung spheroid cells contain progenitor cells and mediate regeneration in rodents with bleomycin-induced pulmonary fibrosis. Stem Cells Transl. Med. 4, 1265–1274 (2015).10.5966/sctm.2015-0062 ↗
7. Dinh, P. C. et al. Derivation of therapeutic lung spheroid cells from minimally invasive transbronchial pulmonary biopsies. Respir. Res. 18, 132 (2017).10.1186/s12931-017-0611-0 ↗
8. Cores, J. et al. Safety and efficacy of allogeneic lung spheroid cells in a mismatched rat model of pulmonary fibrosis. Stem Cells Transl. Med. 6, 1905–1916 (2017).10.1002/sctm.16-0374 ↗
9. Dinh, P.-U. C. et al. Inhalation of lung spheroid cell secretome and exosomes promotes lung repair in pulmonary fibrosis. Nat. Commun. 11, 1064 (2020).10.1038/s41467-020-14344-7 ↗
10. Jiang, S., Zhang, X. & Du, L. Therapeutic antibodies and fusion inhibitors targeting the spike protein of SARS-CoV-2. Expert Opin. Ther. Targets 17, 1–7 (2020).10.1080/14728222.2020.1820482 ↗
11. Li, Q. et al. The impact of mutations in SARS-CoV-2 spike on viral infectivity and antigenicity. Cell 182, 1284–1294.e1289 (2020).10.1016/j.cell.2020.07.012 ↗
12. Zhang, L. et al. SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity. Nat. Commun. 11, 6013 (2020).10.1038/s41467-020-19808-4 ↗
13. Cores, J. et al. A pre-investigational new drug study of lung spheroid cell therapy for treating pulmonary fibrosis. Stem Cells Transl. Med. 9, 786–798 (2020).10.1002/sctm.19-0167 ↗
14. Hamming, I. et al. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J. Pathol. 203, 631–637 (2004).10.1002/path.1570 ↗
15. Zhang, H., Penninger, J. M., Li, Y., Zhong, N. & Slutsky, A. S. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med. 46, 586–590 (2020).10.1007/s00134-020-05985-9 ↗
16. Lan, J. et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature 581, 215–220 (2020).10.1038/s41586-020-2180-5 ↗
17. Lei, C. et al. Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig. Nat. Commun. 11, 2070 (2020).10.1038/s41467-020-16048-4 ↗
18. Kruse, R. L. Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China. F1000Research 9, 72 (2020).10.12688/f1000research.22211.2 ↗
19. Fang, R. H., Luk, B. T., Hu, C.-M. J. & Zhang, L. Engineered nanoparticles mimicking cell membranes for toxin neutralization. Adv. Drug Deliv. Rev. 90, 69–80 (2015).10.1016/j.addr.2015.04.001 ↗
20. Rao, L., Tian, R. & Chen, X. Cell-membrane-mimicking nanodecoys against infectious diseases. ACS Nano 14, 2569–2574 (2020).10.1021/acsnano.0c01665 ↗
21. Zhang, Q. et al. Cellular nanosponges inhibit SARS-CoV-2 infectivity. Nano Lett. 20, 5570–5574 (2020).10.1021/acs.nanolett.0c02278 ↗
22. Rao, L. et al. A biomimetic nanodecoy traps Zika virus to prevent viral infection and fetal microcephaly development. Nano Lett. 19, 2215–2222 (2019).10.1021/acs.nanolett.8b03913 ↗
23. Wei, X. et al. T-cell-mimicking nanoparticles can neutralize HIV infectivity. Adv. Mater. 30, e1802233 (2018).10.1002/adma.201802233 ↗
24. Henry, B. D. et al. Engineered liposomes sequester bacterial exotoxins and protect from severe invasive infections in mice. Nat. Biotechnol. 33, 81–88 (2015).10.1038/nbt.3037 ↗
25. Hoegger, M. J. et al. Assessing mucociliary transport of single particles in vivo shows variable speed and preference for the ventral trachea in newborn pigs. Proc. Natl Acad. Sci. USA 111, 2355–2360 (2014).10.1073/pnas.1323633111 ↗
26. Geiser, M. Update on macrophage clearance of inhaled micro- and nanoparticles. J. Aerosol Med. Pulm. Drug Deliv. 23, 207–217 (2010).10.1089/jamp.2009.0797 ↗
27. Zhou, Y. et al. Pathogenic T cells and inflammatory monocytes incite inflammatory storm in severe COVID-19 patients. Natl Sci. Rev. 7, 998–1002 (2020).10.1093/nsr/nwaa041 ↗
28. Wang, C. et al. Alveolar macrophage dysfunction and cytokine storm in the pathogenesis of two severe COVID-19 patients. EBioMedicine 57, 102833 (2020).10.1016/j.ebiom.2020.102833 ↗
29. Guo, C. et al. Single-cell analysis of two severe COVID-19 patients reveals a monocyte-associated and tocilizumab-responding cytokine storm. Nat. Commun. 11, 3924 (2020).10.1038/s41467-020-17834-w ↗
30. Florindo, H. F. et al. Immune-mediated approaches against COVID-19. Nat. Nanotechnol. 15, 630–645 (2020).10.1038/s41565-020-0732-3 ↗
31. Shin, M. D. et al. COVID-19 vaccine development and a potential nanomaterial path forward. Nat. Nanotechnol. 15, 646–655 (2020).10.1038/s41565-020-0737-y ↗
32. Rao, L. et al. Decoy nanoparticles protect against COVID-19 by concurrently adsorbing viruses and inflammatory cytokines. Proc. Natl Acad. Sci. USA 117, 27141–27147 (2020).10.1073/pnas.2014352117 ↗